HOUSTON--(BUSINESS WIRE)--Pulmotect, Inc. (www.pulmotect.com), a Houston-based biotechnology company, has been awarded $7.1 million by the Cancer Prevention & Research Institute of Texas (CPRIT) to advance its novel product, PUL-042, which offers the promise of better protecting patients receiving chemotherapy from infection, allowing for significantly higher treatment success. This award, when matched with the Company’s other funding, should allow the Company’s lead product to progress through preclinical, Phase I and Phase II trials.
